Virpax Pharmaceuticals 8-K Report: Key Insights & Updates
Based on the provided XML snippet from the financial report, here are the key pieces of information extracted:
- Entity Information:
- Company Name: Virpax Pharmaceuticals, Inc.
- CIK (Central Index Key): 0001708331
- SEC File Number: 001-40064
- EIN (Employer Identification Number): 82-1510982
- Address: 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312
- Phone Number: (610) 727-4597
- Filing Type:
- Form Type: 8-K (This is typically used to report unscheduled material events or corporate changes.)
- Dates:
- Report Date: December 30, 2024 (This is both the start and end date of the reporting period for this particular filing.)
- Stock Information:
- Common Stock Par Value: $0.00001 per share
- Ticker Symbol: VRPX
- Exchange: NASDAQ
- Units of Measure:
- Financial amounts are reported in USD (United States Dollar).
- Share quantities are reported in shares.
Insights:
- The filing is a Form 8-K, indicating that the company is likely reporting a significant event, which could include financial results, acquisition information, or other important corporate developments.
- The par value of the common stock is extremely low, which may suggest a high number of shares outstanding or a capital structure that prioritizes flexibility in capital raising.
- The presence of a contact number indicates that the company is open to communication, which can be important for investors seeking clarity on the report or the company's operations.
- As a publicly traded entity on NASDAQ, Virpax Pharmaceuticals, Inc. is subject to regular reporting requirements, which may provide transparency into its financial health and operational performance over time.
This data can help investors and analysts understand the company's current status and potential developments following the report date.